HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.

Abstract
Lariciresinol is a dietary lignan that accounts for a significant portion of the total phytoestrogen intake from Western foods. Recent epidemiological studies suggest that high dietary intake of lignans and lariciresinol is associated with reduced breast cancer risk. However, no causal relationship between lariciresinol intake and breast cancer development has been established. In this study, we investigated for the first time the effects and possible mechanisms of action of lariciresinol on hormone responsive mammary cancer in vivo in dimethylbenz[a]anthracene induced mammary cancer in rats, and in human MCF-7 breast cancer xenografts in athymic mice. For tumor bearing rats, lariciresinol (3 or 15 mg/kg of body weight) or vehicle was administered p.o. daily for 9 weeks. For E2-maintained ovariectomized athymic mice bearing orthotopic MCF-7 tumors, control diet (AIN-93G) or lariciresinol containing diet (AIN-93G supplemented with 20 or 100 mg of lariciresinol/kg of diet) was administered for 5 weeks. In both models, lariciresinol administration inhibited the tumor growth and tumor angiogenesis. In MCF-7 cells, enterolactone significantly inhibited the E2-stimulated VEGF secretion. Moreover, in MCF-7 xenografts, lariciresinol administration enhanced tumor cell apoptosis and increased estrogen receptor beta expression. Lariciresinol and its further metabolites secoisolariciresinol, enterodiol and enterolactone were found in serum of both rats and athymic mice confirming a similar lignan metabolism pattern as in humans. These findings indicate conceivable importance of dietary lignan lariciresinol in inhibition of breast cancer development.
AuthorsNiina M Saarinen, Anni Wärri, Ruud P M Dings, Maarit Airio, Annika I Smeds, Sari Mäkelä
JournalInternational journal of cancer (Int J Cancer) Vol. 123 Issue 5 Pg. 1196-204 (Sep 01 2008) ISSN: 1097-0215 [Electronic] United States
PMID18528864 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Butylene Glycols
  • Carcinogens
  • Estrogen Receptor alpha
  • Estrogen Receptor beta
  • Furans
  • Lignans
  • Phytoestrogens
  • Receptors, Progesterone
  • 9,10-Dimethyl-1,2-benzanthracene
  • lariciresinol
  • 2,3-bis(3'-hydroxybenzyl)butane-1,4-diol
  • secoisolariciresinol
  • 4-Butyrolactone
  • 2,3-bis(3'-hydroxybenzyl)butyrolactone
Topics
  • 4-Butyrolactone (analogs & derivatives, blood)
  • 9,10-Dimethyl-1,2-benzanthracene
  • Angiogenesis Inhibitors (pharmacology)
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Apoptosis (drug effects)
  • Butylene Glycols (blood)
  • Carcinogens
  • Cell Proliferation (drug effects)
  • Dietary Supplements
  • Estrogen Receptor alpha (metabolism)
  • Estrogen Receptor beta (metabolism)
  • Female
  • Furans (blood, pharmacology, therapeutic use)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Lignans (blood, pharmacology, therapeutic use)
  • Mammary Neoplasms, Experimental (blood, blood supply, chemically induced, drug therapy, pathology)
  • Mice
  • Mice, Nude
  • Ovariectomy
  • Phytoestrogens (blood)
  • Rats
  • Receptors, Progesterone (metabolism)
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: